Paclitaxel Coated Balloons (Optilume) Demystified Knowing When To Say Yes, No, or Wait
Jay Simhan, MD, FACS, explores the role of Paclitaxel-coated balloons, specifically Optilime, in treating urethral strictures.
Read More
Latest Videos
Intermediate-Risk NMIBC/BCG Naïve: Treatment of Choice
Leonard G. Gomella, MD, FACS, explores bladder cancer treatment, particularly in the context of intermediate-risk, BCG-naïve disease.
Read More
Point Counterpoint: Risk Stratification for Biopsy – Biomarkers
Juan Javier-DesLoges, MD, MS, focuses on contemporary advancements in prostate cancer detection, emphasizing the integration of biomarkers and MRI for biopsy decision-making. In this 5-minute presentation, he references recent guidelines, which advocate biomarkers and MRI as tools for determining the necessity of biopsies. Studies comparing biomarkers such as 4K, PHI, SelectMDx, and XODX illustrate their ability to enhance the specificity and accuracy of cancer detection compared to PSA alone.
Dr. Javier-DesLoges stresses that MRI further refines risk stratification when combined with biomarkers. He underscores the complementary role of these tools, advocating their combined use to optimize diagnostic outcomes for patients with intermediate PSA levels.
Read More
Point Counterpoint: Risk Stratification for Biopsy – MRI
Peter A. Pinto, MD, underscores the evolving role of MRI as a critical biomarker in urologic oncology, particularly for prostate cancer detection, staging, and treatment planning.
In this 12-minute conversation, Dr. Pinto highlights MRI’s unique position as a diagnostic and procedural adjunct, emphasizing its ability to improve biopsy accuracy, reduce over-diagnosis of low-grade cancers, and enhance focal therapy targeting. He shares that MRI provides actionable insights that enhance clinical decision-making by correlating radiologic findings with pathological outcomes. Further, the potential of MRI as a screening tool is explored, with promising advancements in shorter, contrast-free scans. Dr. Pinto also addresses the integration of AI for tumor identification, segmentation, and quality control, presented as a pathway to overcoming these limitations.
Read More
Adaptive Radiotherapy
In this 23-minute presentation, Richard D. Stock, MD, explores integrating artificial intelligence in radiation oncology, focusing on adaptive radiation therapy (ART). Three categories of ART—offline, online, and real-time—are detailed, explaining their respective timelines, imaging technologies, and resource requirements. The discussion critically evaluates ART in prostate cancer, where anatomical shifts due to bladder or rectal changes can influence treatment accuracy.
Examples of imaging technologies like MRI and PET scans are discussed for their contributions to ART’s precision and potential to adapt treatment based on tumor shrinkage or biological response. Comparative studies from the Netherlands and other institutions demonstrate ART’s ability to refine target margins, decrease normal tissue exposure, and predict patient outcomes more accurately.
As ART shows promise in improving treatment precision, Dr. Stock emphasizes its potential for advancing radiation oncology, driven by technological innovation and ongoing research.
Read More